For HER2 subtype, [34] confirms that agents targeting GAB2 or GAB2-dependent pathways may be useful for treating breast tumors that overexpress HER2, and thus we include GAB2 as a correlated gene for HER2 type breast cancer. This evidence concerns the gene ERBB2 and breast cancer.